ClinicalTrials.Veeva

Menu

Efficacy of Contingency Management in the Treatment of Adolescents With Cannabis Use Disorders

H

Hospital Clinic of Barcelona

Status

Unknown

Conditions

Marijuana Abuse

Treatments

Behavioral: Standard treatment
Behavioral: Standard Treatment Plus Contingency Management Program

Study type

Interventional

Funder types

Other

Identifiers

NCT00878852
PI08/90331
4363/2008 (Ethics Comitee HCP)

Details and patient eligibility

About

Cannabis use among Spanish adolescents has been increasing in the last decade. It has been related to poor school achievement, delinquency, substance use and psychiatric disorders. Furthermore, psychoactive substance use in adolescents presenting psychiatric disorders can result in the development of substance use disorders or the worsening of psychopathology. Thus, there's an urge to develop efficient interventions in the treatment of these disorders. Therapeutic approaches based on cognitive-behavioural therapy and motivational interviewing have demonstrated a limited efficacy in this population. Programs based on contingency management have been reported to be useful both in adult and adolescents, too. But it still remains unclear whether a combination of these therapeutic approaches is feasible and brings a better cost-benefit relation.

The investigators' project aims to evaluate the added benefits of supplementing a standard intervention on cannabis use, based on combined approach that includes motivational and cognitive-behavioural elements, with a contingency management program. Therefore, pre and post-treatment evaluation will be carried forward in a sample of 30 adolescents (aged 12-18) that initiate treatment for cannabis use related disorder at the Child and Adolescent Psychiatry Department of the Hospital Clinic in Barcelona. Participants will be randomly assigned to a standard treatment group or an experimental group in which standard treatment will be supplemented with a contingency management protocol. As a secondary objective, a prospective assessment of neuropsychological performance related to cannabis use or abstinence will be carried forward.

Enrollment

30 estimated patients

Sex

All

Ages

12 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Presence of DSM-IV-TR criteria of cannabis abuse and/or dependence
  • Signed informed consent

Exclusion criteria

  • Mental retardation
  • Presence of a substance use disorder other than nicotine or cannabis
  • Severe or unstable medical
  • Presence at the moment of inclusion of severe acute psychopathology (acute psychotic symptoms, severe depressive symptoms, suicidal ideation)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

30 participants in 2 patient groups

Standard treatment
Active Comparator group
Description:
Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of a 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001)
Treatment:
Behavioral: Standard treatment
Experimental
Experimental group
Description:
Participants randomly assigned to this group will received standard treatment (including 12 session therapy program) supplemented with an intervention with a contingency management program, designed to improve adherence and efficacy of the treatment program.
Treatment:
Behavioral: Standard Treatment Plus Contingency Management Program

Trial contacts and locations

1

Loading...

Central trial contact

Javier Goti, M.D

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems